SecBot SecBot
6-K ·Filed Apr 10, 2026

GLAXF

GSK plc
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001654954-26-003393
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine share buyback within an announced program. While it slightly reduces shares outstanding which could support EPS, the transaction size is relatively small compared to the company's market cap. Monitor for continued buyback activity as an indicator of management's capital allocation priorities, but this single transaction has minimal immediate impact on valuation.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
GLAXF ▼ -7.69% at T+60d
NEUTRAL call -7.69% · α vs SPY -18.02% · entry $29.25 → $27.00
Entry = T+0 close
Apr 10, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.98%
$29.25
settled 7mo ago
T+5d
+0.85%
call +0.85% · α -3.65%
$29.50
settled 6mo ago
T+20d
-13.64%
call -13.64% · α -22.17%
$25.26
settled 6mo ago
T+60d
-7.69%
call -7.69% · α -18.02%
$27.00
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

GSK plc repurchased 330,000 ordinary shares on April 9, 2026, at a volume-weighted average price of 2,139.38 GBp per share, as part of its ongoing buyback program. This transaction increases the company's treasury holdings to 257.8 million shares, representing 6.35% of total voting rights.

Key Facts

  • GSK repurchased 330,000 ordinary shares on April 9, 2026
  • Volume-weighted average price was 2,139.38 GBp per share
  • Treasury shares now total 257,787,615, representing 6.35% of voting rights
  • Purchase was executed through BNP Paribas SA as part of existing buyback program
  • Since February 17, 2026, company has purchased 17,896,521 ordinary shares

Financial Impact

Approximately $7.06 million spent on repurchase (330,000 shares × £21.3938)

shares outstandingtreasury stockearnings per share (potential future impact)

Risk Factors

  • Dilution of buyback impact if company issues new shares
  • Program could be suspended if financial conditions change

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003393
Document: 0001654954-26-003393-index-headers.html0001654954-26-003393
Document: 0001654954-26-003393-index.html0001654954-26-003393
Document: 0001654954-26-003393.txt0001654954-26-003393
51 reports for GLAXF
Performance horizon
46% Hit rate @ T+5 6 of 13 directional calls Went positive at some point 7 of 13 best @ T+20▲ +9.49%Jun 9, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
TypeNow
Jun 10, 2026
19w ago
6-K
NEUTRAL ★ 1/10
$25.12 $25.25▲ +0.52%▼ −1.62%$26.12 (+3.98%)
Jun 9, 2026
20w ago
6-K
NEUTRAL ★ 1/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 9, 2026
20w ago
6-K
BULLISH ★ 7/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
May 28, 2026
21w ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$26.12 (+6.27%)
May 27, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$26.12 (+2.15%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 22, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$26.12 (+0.46%)
Showing 10 of 51

US Market Status

Market Closed — Opens Thu (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026